Clinical Trial Update: Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a personalized antisense oligonucleotide targeting ATN1 (nL62541) in Dentatorubral-Pallidoluysian Atrophy; the Phase 1/2 study is acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dentatorubral-pallidoluysian Atrophy

Drugs mentioned

• nL62541 (ATN1-targeted antisense oligonucleotide)

Snippet

Sponsor: n-Lorem Foundation | Conditions: Dentatorubral-Pallidoluysian Atrophy | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING